Bottom Line: Future market access in IHS depends on implementation of a sovereign account model that recognizes Tribal nations as high-agility delivery networks prioritizing clinical autonomy, cultural integration, and long-term medical self-sufficiency. For medical device and pharmaceutical manufacturers, the Indian Health Service (IHS) has historically been approached as a traditional federal payer similar to the Veterans Health Administration (VHA) or Defense Health Agency

Bottom Line By pivoting its 2025–2030 Strategic Plan toward a high-velocity functional mandate, the DHA is prioritizing mission-availability. Manufacturers must take this moment to evaluate current messaging and recalibrate their own messaging to show a direct reduction in warfighter downtime. The Defense Health Agency (DHA) is currently navigating a fundamental structural evolution between its established 2025–2030 Strategic Plan and a new set of performance-driven mandates

Bottom Line: In a rapidly evolving federal healthcare environment, manufacturer success in 2026 hinges on an organization’s ability to execute against five critical catalysts that are currently reshaping the market landscape. The federal healthcare landscape - encompassing the Department of Veterans Affairs (VA) and the Department of Defense (DoD) - is entering a period of significant structural transition. Several regulatory and administrative events will change how manufact

Bottom Line: The VA/DoD procurement model provides pharmaceutical manufacturers with a predictable, efficient, and simplified channel advantage by using the statutory Federal Ceiling Price (FCP) and a direct-purchase, single-payer structure that eliminates complex negotiations, post-sale rebates, and private intermediaries. The procurement model utilized by the nation's largest integrated healthcare systems, the Department of Veterans Affairs (VA) and the Department of Defens